Catalyst Enterprise Value Over E B I T D A from 2010 to 2024
| CPRX Stock | USD 21.19 0.29 1.35% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 19.03519516 | Current Value 19.99 | Quarterly Volatility 18.69348354 |
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
Catalyst | Enterprise Value Over E B I T D A |
Latest Catalyst Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Catalyst Pharmaceuticals over the last few years. It is Catalyst Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Catalyst Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (2.50) | |
| Coefficient Of Variation | (747.11) | |
| Mean Deviation | 12.72 | |
| Median | (3.47) | |
| Standard Deviation | 18.69 | |
| Sample Variance | 349.45 | |
| Range | 75.788 | |
| R-Value | 0.79 | |
| Mean Square Error | 140.55 | |
| R-Squared | 0.63 | |
| Significance | 0.0004 | |
| Slope | 3.31 | |
| Total Sum of Squares | 4,892 |
Catalyst Enterprise Value Over E B I T D A History
About Catalyst Pharmaceuticals Financial Statements
Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 19.04 | 19.99 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.